Publication on novel Technology for Zolmitriptan in Migraine, announced by Zosano

Zosano Pharma Corporation, a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, announced the recent publication of a peer-reviewed paper regarding ADAM technology for the delivery of zolmitriptan in the Journal of Pharmaceutics.

“Our in vitro study presents guidance on use of the appropriate skin model to assess intracutaneous delivery of compounds using the ADAM platform.  This particular study, assessing the intracutaneous delivery of zolmitriptan, is the first of its kind and we are excited to present the results,” said Hayley Lewis, senior vice president, operations at Zosano Pharma.

Data published in the Journal of Pharmaceutics evaluated how different in vitro skin models influenced the absorption of zolmitriptan with ADAM technology. This standardized method of testing produced a model for evaluating the efficiency of intracutaneous delivery of zolmitriptan.  The model will be helpful as Zosano continues to assess the efficiency of small molecules delivered with ADAM.

About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Migraine, visit https://pharmascroll.com/news-category/migraine/

News Source: Zosano website

Image Source: https://preziland.com/prezi-templates/new-technology-prezi-template-with-3d/